# Determined to realize a future in which people with cancer live longer and better than ever before

Syndax

2Q21 EARNINGS PRESENTATION

# Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

# Syndax pipeline targets indications with significant unmet need

## Menin Inhibitor Program (SNDX-5613)

- Target validated for acute leukemias
- AUGMENT-101 enrollment ongoing
- Ph 1 data presented 2Q21
- Accelerated path to approval

## Anti-CSF-1R Program (Axatilimab)

- Macrophage driven diseases
- Ph 1 data validates target for cGVHD, additional inflammatory / fibrotic opportunities
- Pivotal trial (AGAVE-201) ongoing

## Development Opportunities

- Focused on expanding clinical pipeline through development and in-licensing

# Positive initial Phase 1 results establish SNDX-5613 as the leading Menin-MLL interaction inhibitor

## Well-tolerated

- No discontinuations for drug-related AEs
- Well tolerated through multiple cycles

## Clear Evidence of Single Agent Activity

- Overall response rate*: 15/31 (48%)
  - 7/31 (23%) CR/CRh
  - 10/15 (67%) $CR_{MRD-}$

## PK / PD, RP2D

- Dose meeting RP2D criteria identified
- Robust gene expression changes confirm MOA

** Overall response rate includes CR + CRh + CRp + CRi + MLFS observed among pts enrolled with MLLr or NPM1c Acute Leukemia*

# We have rapidly identified doses that meet our RP2D criteria




*Data cutoff date: June 30, 2021*

# On track for potential NDA submission in 2023



# Moving to frontline could meaningfully expand market potential

## Potential best/first-in-class agent

- Clear efficacy in refractory, advanced NPM1 and MLLr acute leukemia
- High percentage of MRD negative responses

## Profile supports use in frontline and maintenance

- Well-tolerated safety profile, no discontinuations due to treatment related AE
- Preclinical data supports combos with venetoclax[1], chemotherapy[2]
- Pediatric formulation established




1. Carter, B., et al., Blood 2021, 2. Data on file

# Axatilimab: CSF-1R mAb with potential best-in-class profile




***Anticipate reporting results for all 40 patients treated in the Phase 1/2 in 4Q21***

# AGAVE-201 : ongoing global pivotal trial for Axatilimab in chronic GVHD

**Inclusion criteria:**

- 6 years and older
- Recurrent or refractory active cGVHD after at least 2 lines of systemic therapy




***Primary Endpoint: Objective Response Rate (ORR) by 2014 NIH GVHD Criteria***

***Key Secondaries: Duration of response, improvement in modified Lee Symptom Scale***

# Proven ability to build the pipeline

Business development continues to be a core strength of our business

Clinical development leadership enables competitive advantage

Established relationships enhance identification and access to quality assets

**From UCB**

**Axatilimab**

**From Allergan/Vitae**

**Menin-MLL inhibitors**



# Financial highlights and FY 2021 financial guidance

| Ticker | SNDX (NASDAQ) |
|---|---|
| Cash and short-term investments (as of June 30, 2021) | $253.1 million |
| Shares Outstanding* (as of June 30, 2021) | 51.9 million |

| 3Q and 2021 Operating Expense Guidance | | |
|---|---|---|
| | 3Q 2021 | FY 2021 |
| Research and Development | $25-30 million | $90-100 million |
| Total Operating Expenses^ | $30-35 million | $110-120 million |

* *Includes 48.6 million common shares and pre-funded warrants to purchase 3.3 million common shares;*
^ *Includes ~$2.5 million non-cash stock compensation expense per quarter*

# Thank you. Questions?

Syndax